Since the beginning of the global COVID-19 crisis, our focus has been on patients, our employees, supporting our communities, as well as the healthcare staff working on the frontlines. 

The COVID-19 pandemic is changing the way we view health care. It

has brought to the forefront of public conversation sobering truths about how social and racial disparities impact the health outcomes of underserved populations in the United States. Often, we attribute an individual’s health solely to the quality of health care they receive when in fact, a host of factors that occur outside clinical walls can play an even greater role in a person’s well-being. Social Determinants of Health (SDH) are the conditions in which people are born, grow, live, work and age, such as socioeconomic factors, housing, physical environment, education, employment, social support and access to health care. SDH can affect a wide range of health outcomes and quality of life, especially for individuals battling chronic illnesses like epilepsy.

At UCB, we are committed to supporting the psoriasis community and working to improve the future for those living with the disease. In honor of Psoriasis Awareness Month, we’re shining a spotlight on the over 7 million people in the U.S. impacted by psoriasis every day.

“They have a band!” Justin Gorman eagerly answered when his wife asked him how his interview with UCB went in May 2017. For Justin, the employee-formed band, UCB Rocks, was not just a unique feature to UCB, but also a way for him to integrate his personal love of music, his career, and his relationships with other colleagues.

Read from Anita Moser, Michael Davis, Dharmendra Sahay as they outline UCB's measured approach to scaling our AI capabilities. The article was originally published in PharmExec.

At UCB, we know to successfully bring value to the lives of patients we need to cultivate a healthy and connected culture within. This is why UCB provides its employees at its U.S. Headquarters in Atlanta, Georgia and across the U.S. with the tools and facilities to prioritize their well-being.

Today, UCB issued the following statement jointly from Camille Lee, Head of U.S. Immunology, and Jeff Stark, M.D., Head of U.S. Medical Immunology, on the recent update by the ICD-10 Coordination and Maintenance Committee (a subcommittee of the U.S. Centers for Disease Control and Prevention) to endorse and make public that non-radiographic axial spondyloarthritis (nr-axSpA) will be formally indexed to ICD-10 sub category M46.8; these changes will be effective for diagnoses starting October 1, 2020 and more information is available on the Centers for Medicare & Medicaid Service (CMS) website which outlines the specific coding changes in greater detail:

At UCB, patients are at the heart of everything we do. Read more from Brad Chapman, U.S. Head of Internal Operations and West Ecosystem - Neurology, on how our agile ways of working are helping us keep our commitment to patients, physicians, and the communities we serve in a work-from-home world.

Despite the unprecedented events stemming from the novel coronavirus, we are pleased to continue our mission of investing in the next generation of the work force by welcoming 18 student interns to our first virtual internship program.

At UCB, we know we’re stronger when we work together. Read more from Patty Fritz, VP of U.S. Corporate Affairs, about how UCB adapted in response to the COVID-19 pandemic to met the new unique needs of the patients, caregivers, health care providers, and health systems we’re committed to serving.